UPDATE: Amylyx Pharmaceuticals (AMLX) - The Alarm Goes Off Tomorrow
LUCIDITY topline drops before the open on August 18 at 8:00 a.m. ET, and the stock has bled 11.4% into the print — here is exactly what the number has to look like to matter.
Biotech Distilled
Biotech Distilled
Latest episodes
UPDATE: Ardelyx (ARDX) - The Commercial Chief Walks
Eleven days after management cut IBSRELA guidance ~15% and blamed payer utilization management, the Chief Commercial Officer resigned — for a pre-commercial company.
UPDATE: Coherus Oncology (CHRS) - They Funded the Coin Flip
$55M of secured debt from Innovatus plus a contingent-value-rights dividend on the leftover biosimilar assets — Coherus bought itself the runway to reach the October casdozokitug readout
UPDATE: EyePoint (EYPT) - LUGANO Missed. Nine Patients Broke the Thesis.
DURAVYU missed the primary BCVA endpoint in the full LUGANO dataset and only cleared non-inferiority after management excluded 9 of 211 patients in an ad hoc analysis.
Lineage Cell Therapeutics (LCTX) — Scientific Deep Dive for OpRegen, OPC1, and Pipeline Products
The Bleb Is the Drug: How Surgical Coverage, Not Cell Count, Decides OpRegen’s Fate
THE DISTILLED 3: Top Plays for the Week of August 17, 2026
This Substack is reader-supported.
Biotech Distilled Weekly Movers (2026-08-14)
This Substack is reader-supported.
UPDATE: Achieve Life Sciences (ACHV) - The $150M Insurance Policy
Achieve opened a $150M at-the-market program with Jefferies today, funding launch and the vaping Phase 3 without waiting on the $174M approval-triggered warrants — and the stock rose 12.1% anyway.
UPDATE: Quoin Pharmaceuticals (QNRX) - The Clock Runs Faster Than the Catalysts
Q2 leaves $10.8M against an $8.0M half-year burn and an unchanged going-concern flag — while the one readout that actually matters, the placebo-controlled POC 1, went missing from the update entirely.
UPDATE: Capricor Therapeutics (CAPR) — The August 22 Binary Just Got Cancelled
The 10-Q discloses that FDA has agreed to review a BLA amendment with 24-month HOPE-3 extension data supporting a “refined indication,” with the PDUFA date extended accordingly. CAPR +58% to $6.65.
UPDATE: Aptevo Therapeutics (APVO) - They Just Locked Their Own Piggy Bank
Q2 brings cash down to $9.8M against $13.4M of half-year burn — and the fine print of Monday’s $4.5M raise bars Aptevo from touching its $66.8M Yorkville lines or its ATM for 12 months after approval
UPDATE: Cue Biopharma (CUE) - A $153 Million Loss That Isn’t a Loss
Q2 prints a $153.1M net loss on a company with a ~$250M market cap — and the stock is up 27% since August 3.
UPDATE: Taysha Gene Therapies (TSHA) - Follow the Money, Finally
RA Capital’s amended 13G shows 23.6M shares plus pre-funded warrants for 52.1M more — an economic stake of ~75.7M shares behind a 9.99% blocker, disclosed the same week the stock gave back 10.9%.
UPDATE: Replimune (REPL) - The Confirmatory Clock Just Moved to 2030
Q1 numbers land with the going-concern paragraph lifted and a real Chief Commercial Officer hired — but buried in the release is an IGNYTE-3 overall survival readout in 2030.
UPDATE: PMV Pharma (PMVP) - The Going Concern Flag Goes Up
Auditors’ language just changed: $79.4M cash, ~$17M/quarter burn, and a formal “substantial doubt” warning — filed the same morning PMV confirmed PYNNACLE enrollment is complete.
UPDATE: NRx Pharmaceuticals (NRXP) - The ATM Never Went Dormant
The Q2 10-Q shows $8.4M of ATM sales in the same quarter as the $20.7M underwritten deal, the Kadima acquisition terminated for cause, and a stated runway only through Q1 2027 — on $26.7M of cash.
UPDATE: Medicenna Therapeutics (MDNAF) - Two Oral Slots, One Slipped IND, and Sorbie Still in Forward-Looking Tense
Q1 FY2027 upgrades both lead assets to oral presentations at upcoming conferences — a partner-grade venue for partner-gated bizaxofusp.
UPDATE: Marker Therapeutics (MRKR) - The Catalyst That Didn’t Show Up
Q2 R&D fell 65% to $1.5M and the 1H 2026 APOLLO readout I've been circling since January never printed. A $4.2M Department of War grant is the good news; the burn-rate collapse is the tell.
UPDATE: Helus Pharma (HELP) - A Permanent CEO, a Clean DDI Study, and 11 Million New Shares
Q1 FY2027 delivers the Intra-Cellular hire I wanted and the drug-interaction data the adjunctive thesis needed — while the share count quietly climbed from 62M to 73M and the stock ripped +48%
UPDATE: Crinetics Pharmaceuticals (CRNX) - The Antitrust Gate Opens
HSR expired August 12, Austria/Germany/Australia cleared, special meeting set for August 28, and Vertex now guides to an early-September close. The last real risk in the arb just got retired.